Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.

Download DocumentationJuno Corporate Presentation - November 2017
Webcast ImageWebcast - Live
Juno Therapeutics at Evercore ISI Biopharma Catalyst / Deep Dive Conference
November 29, 2017 at 8:45 a.m. ET
Juno Therapeutics at Evercore ISI Biopharma Catalyst / Deep Dive Conference
Wednesday, November 29, 2017 8:45 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
Juno Therapeutics at 26th Annual Credit Suisse Healthcare Conference
November 08, 2017 at 9:15 a.m. MT
Juno Therapeutics at 26th Annual Credit Suisse Healthcare Conference
Wednesday, November 8, 2017 9:15 a.m. MT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
Q3 2017 Juno Therapeutics Earnings Conference Call
November 01, 2017 at 1:30 p.m. PT
Q3 2017 Juno Therapeutics Earnings Conference Call
Wednesday, November 1, 2017 1:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Recent News

DateTitle 
Nov. 06, 2017Juno Therapeutics to Present at November 2017 Investor ConferencesPrinter Friendly Version
Nov. 01, 2017Juno Therapeutics Reports Third Quarter 2017 Financial ResultsPrinter Friendly Version
Nov. 01, 2017Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASHPrinter Friendly Version
Oct. 25, 2017Juno Therapeutics to Report Third Quarter 2017 Financial Results on Wednesday, November 1Printer Friendly Version

Upcoming Events

DateTitle
Nov. 29, 2017
8:45 a.m. ET
Juno Therapeutics at Evercore ISI Biopharma Catalyst / Deep Dive Conference

Past Events

DateTitle
11/08/17 9:15 a.m. MT
Juno Therapeutics at 26th Annual Credit Suisse Healthcare Conference
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
JUNO (Common Stock)
ExchangeNASDAQ
Price$58.64
Change Stock is Up 0.90 (1.56%)
Volume1,422,127
Data as of Nov. 17, 2017 4:00 p.m. ET